IRIS UniCatt

Rossi, Elena
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.985
AS - Asia 3.208
EU - Europa 2.791
SA - Sud America 513
AF - Africa 89
OC - Oceania 11
Continente sconosciuto - Info sul continente non disponibili 4
Totale 10.601
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.858
SG - Singapore 1.677
DE - Germania 716
CN - Cina 657
IT - Italia 550
SE - Svezia 448
BR - Brasile 421
FR - Francia 245
VN - Vietnam 230
UA - Ucraina 146
GB - Regno Unito 140
IE - Irlanda 129
PL - Polonia 121
IN - India 105
BD - Bangladesh 94
ID - Indonesia 88
FI - Finlandia 75
HK - Hong Kong 74
CA - Canada 64
RU - Federazione Russa 60
JP - Giappone 57
IQ - Iraq 42
AR - Argentina 37
MX - Messico 36
AT - Austria 34
NL - Olanda 25
SA - Arabia Saudita 25
ZA - Sudafrica 23
KR - Corea 22
TR - Turchia 22
ES - Italia 17
CI - Costa d'Avorio 16
BE - Belgio 15
PK - Pakistan 15
VE - Venezuela 12
IR - Iran 11
PH - Filippine 11
LT - Lituania 10
PE - Perù 10
UZ - Uzbekistan 10
AU - Australia 9
CL - Cile 9
EC - Ecuador 9
KE - Kenya 9
MA - Marocco 9
TH - Thailandia 9
CH - Svizzera 8
MY - Malesia 8
AE - Emirati Arabi Uniti 7
AZ - Azerbaigian 7
DZ - Algeria 7
HU - Ungheria 7
JM - Giamaica 7
TN - Tunisia 7
UY - Uruguay 6
CO - Colombia 5
KZ - Kazakistan 5
LV - Lettonia 5
OM - Oman 5
RO - Romania 5
AL - Albania 4
CR - Costa Rica 4
CZ - Repubblica Ceca 4
DK - Danimarca 4
EG - Egitto 4
JO - Giordania 4
NP - Nepal 4
A2 - ???statistics.table.value.countryCode.A2??? 3
BY - Bielorussia 3
EE - Estonia 3
HN - Honduras 3
MK - Macedonia 3
NI - Nicaragua 3
PY - Paraguay 3
SN - Senegal 3
DO - Repubblica Dominicana 2
ET - Etiopia 2
GA - Gabon 2
GT - Guatemala 2
IL - Israele 2
KG - Kirghizistan 2
KH - Cambogia 2
LB - Libano 2
MM - Myanmar 2
NO - Norvegia 2
PA - Panama 2
PR - Porto Rico 2
PT - Portogallo 2
SK - Slovacchia (Repubblica Slovacca) 2
TW - Taiwan 2
TZ - Tanzania 2
AD - Andorra 1
AO - Angola 1
BG - Bulgaria 1
BH - Bahrain 1
BO - Bolivia 1
BT - Bhutan 1
BZ - Belize 1
CG - Congo 1
DM - Dominica 1
Totale 10.584
Salva come PNG Salva come JPEG
Città #
Singapore 1.056
Chandler 485
Ashburn 389
San Jose 359
Dallas 163
Rome 138
Beijing 130
Dublin 123
New York 103
Wilmington 94
Los Angeles 91
Warsaw 89
Jacksonville 86
San Mateo 86
Fairfield 80
Milan 80
Ho Chi Minh City 79
Jakarta 79
Munich 76
Lauterbourg 70
Ann Arbor 66
Hong Kong 66
Hanoi 63
Houston 63
Hefei 62
Boston 61
Cattolica 61
Dearborn 61
Nanjing 61
Woodbridge 56
Frankfurt am Main 47
Tokyo 47
Seattle 44
São Paulo 44
Chicago 41
Marseille 39
Moscow 39
Princeton 38
The Dalles 37
Council Bluffs 35
Hyderabad 33
Redwood City 32
Boardman 28
Helsinki 27
Lawrence 26
Nürnberg 25
Orem 25
Santa Clara 25
Buffalo 23
Detroit 23
Kraków 23
Redmond 23
Toronto 23
Nanchang 22
Nuremberg 22
Cambridge 20
Hangzhou 20
London 19
Bologna 18
Paris 18
St Louis 18
Brooklyn 17
Hebei 17
Mexico City 17
Seoul 17
Washington 17
Abidjan 16
Atlanta 16
Montreal 16
Belo Horizonte 15
Brussels 15
Kent 15
Vienna 15
Guangzhou 14
Leawood 14
Norwalk 14
Da Nang 12
Tianjin 12
Baghdad 11
Chennai 11
Florence 11
Johannesburg 11
Lappeenranta 11
Shanghai 11
Stockholm 11
Changsha 10
Dhaka 10
Düsseldorf 10
Ealing 10
Tashkent 10
Bremen 9
Buenos Aires 9
Mountain View 9
North Bergen 9
Rio de Janeiro 9
San Diego 9
Amsterdam 8
Bexley 8
Haiphong 8
Jeddah 8
Totale 5.852
Salva come PNG Salva come JPEG
Nome #
Risk factors for venous thromboembolism in patients with lymphoma requiring hospitalization 329
Arterial and venous thrombosis in patients with monoclonal gammopathy of undetermined significance: incidence and risk factors in a cohort of 1491 patients. 326
Fondaparinux in pregnancy: Could it be a safe option? A review of the literature. 278
Haemostatic alterations induced by treatment with asparaginases and clinical consequences 243
Venous Thromboembolism in Lymphoma: Risk Stratification and Antithrombotic Prophylaxis 242
A machine-learning parsimonious multivariable predictive model of mortality risk in patients with Covid-19 234
A randomized, double-blind trial of three aspirin regimens to optimize antiplatelet therapy in essential thrombocythemia 225
Impact of Radiotherapy on Pain Relief and Recalcification in Plasma Cell Neoplasms : Long-Term Experience. 201
Risk factor and etiology analysis of ischemic stroke in young adult patients 199
Splanchnic vein thrombosis and myeloproliferative neoplasms: molecular-driven diagnosis and long-term treatment 191
Bone marrow megakaryocytic activation predicts fibrotic evolution of Philadelphia-negative myeloproliferative neoplasms 174
A machine-learning parsimonious multivariable predictive model of mortality risk in patients with Covid-19 169
Venous thromboembolism in multiple myeloma 168
The Aspirin Regimens in Essential Thrombocythemia (ARES) phase II randomized trial design: Implementation of the serum thromboxane B(2) assay as an evaluation tool of different aspirin dosing regimens in the clinical setting 166
Absence of the JAK2 exon 12 mutations in patients with splanchnic venous thrombosis and without overt myeloproliferative neoplasms 165
Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments 161
Contractile reserve of dysfunctional myocardium after revascularization: A dobutamine stress echocardiography study 158
Hydroxyurea-related toxicity in 3,411 patients with Ph'-negative MPN 157
Full donor chimerism after allogeneic hematopoietic stem cells transplant for myelofibrosis: The role of the conditioning regimen 157
Influence of the JAK2 V617F mutation and inherited thrombophilia on the thrombotic risk among patients with essential thrombocythemia 153
Allogeneic Hemopoietic Stem Cell Transplantation for Myelofibrosis: 2021 151
Treatment of primary plasma cell leukemia with high doses of cyclophosphamide, bortezomib, and dexamethasone followed by double autologous HSCT 149
Alternate use of thrombopoietin receptor agonists in adult primary immune thrombocytopenia patients: A retrospective collaborative survey from Italian hematology centers 149
Full donor chimerism after allogeneic hematopoietic stem cells transplant for myelofibrosis: The role of the conditioning regimen 146
Prognostic significance of normalized FDG-PET parameters in patients with multiple myeloma undergoing induction chemotherapy and autologous hematopoietic stem cell transplantation: a retrospective single-center evaluation 145
Assessment of congenital neutropenia in children: common clinical sceneries and clues for management 145
Prevalence of the JAK2 V617F mutation in patients with unprovoked venous thromboembolism of common sites and without overt myeloproliferative neoplasms 144
JAK2 V617F mutational frequency in essential thrombocythemia associated with splanchnic or cerebral vein thrombosis 142
Risk of venous thromboembolism associated with single and combined effects of Factor V Leiden, Prothrombin 20210A and Methylenetethraydrofolate reductase C677T: a meta-analysis involving over 11,000 cases and 21,000 controls 142
Mono/polyclonal free light chains as challenging biomarkers for immunological abnormalities 142
A novel biomarker score for the screening and management of patients with plasma cell proliferative disorders 136
Increased prevalence of the G20210A prothrombin gene variant in acute coronary syndromes without metabolic or acquired risk factors or with limited extent of disease 136
The risk of symptomatic pulmonary embolism due to proximal deep venous thrombosis differs in patients with different types of inherited thrombophilia 134
Inherited thrombophilia: treatment during pregnancy. 129
Obstetric complications and pregnancy-related venous thromboembolism: The effect of low-molecular-weight heparin on their prevention in carriers of factor V Leiden or prothrombin G20210A mutation 128
Splanchnic vein thrombosis and myeloproliferative neoplasms: molecular-driven diagnosis and long-term treatment 126
In families with inherited thrombophilia the risk of venous thromboembolism is dependent on the clinical phenotype of the proband 123
High rate of recurrent venous thromboembolism in patients with myeloproliferative neoplasms and effect of prophylaxis with Vitamin K antagonists 123
Clinical and molecular predictors of fibrotic progression in essential thrombocythemia: A multicenter study involving 1607 patients 120
The C807T/G873A polymorphism in the platelet glycoprotein Ia gene and the risk of acute coronary syndrome in the Italian population 118
D-dimer and reduced-dose apixaban for extended treatment after unprovoked venous thromboembolism: the Apidulcis study 116
Ropeginterferon alfa-2b versus phlebotomy in low-risk patients with polycythaemia vera (Low-PV study): a multicentre, randomised phase 2 trial 115
Testing for inherited thrombophilia and consequences for antithrombotic prophylaxis in patients with venous thromboembolism and their relatives. A review of the Guidelines from Scientific Societies and Working Groups 115
Association of Platelet Thromboxane Inhibition by Low-Dose Aspirin With Platelet Count and Cytoreductive Therapy in Essential Thrombocythemia 115
Splanchnic vein thrombosis in myeloproliferative neoplasms: Risk factors for recurrences in a cohort of 181 patients 112
Reassessment of contractile reserve after revascularization of akinetic myocardium 111
Cerebral sinus-venous thrombosis 110
Coagulopathy in CAR-T: Critical concern or mere blip? 106
Predicting Factors for Seizures after Cerebral Venous Thrombosis: A Retrospective Single Center Cohort Study 106
Leukocytosis is a risk factor for recurrent arterial thrombosis in young patients with polycythemia vera and essential thrombocythemia 106
Isolated light chain deposition disease neuropathy in a patient with multiple myeloma 106
Prednisone vs high-dose dexamethasone in newly diagnosed adult primary immune thrombocytopenia: a randomized trial 103
Benefit-risk profile of cytoreductive drugs along with antiplatelet and antithrombotic therapy after transient ischemic attack or ischemic stroke in myeloproliferative neoplasms 102
Hydroxyurea prevents arterial and late venous thrombotic recurrences in patients with myeloproliferative neoplasms but fails in the splanchnic venous district. Pooled analysis of 1500 cases 101
Methylation Analysis of Urinary Sample in Non-Muscle-Invasive Bladder Carcinoma: Frequency and Management of Invalid Result 100
Long-term pharmacodynamic and clinical effects of twice- versus once-daily low-dose aspirin in essential thrombocythemia: The ARES trial 100
Management of elderly patients with immune thrombocytopenia: Real-world evidence from 451 patients older than 60 years 100
Arterial thrombosis in Philadelphia-negative myeloproliferative neoplasms predicts second cancer: A case-control study 100
Predicting Factors for Seizures after Cerebral Venous Thrombosis: A Retrospective Single Center Cohort Study 98
Structural analysis of protein Z gene variants in patients with foetal losses 96
Efficacy and safety of ruxolitinib and hydroxyurea combination in patients with hyperproliferative myelofibrosis 93
full donor chimerism after allogenic hematopoietic stem cells transplant for myelofibrosis the role of the conditioning regiment 91
Allogeneic Hemopoietic Stem Cell Transplantation for Myelofibrosis: 2021 90
Glycoprotein la C807T qene polymorphism and increased risk of recurrent acute coronary syndromes: A five year follow up 90
Venous thromboembolism in patients with liver diseases 89
Risk of venous thromboembolism associated with single and combined effects of Factor V Leiden, Prothrombin 20210A and Methylenetethraydrofolate reductase C677T: a meta-analysis involving over 11,000 cases and 21,000 controls 88
Indications and use of therapeutic phlebotomy in polycythemia vera: which role for erythrocytapheresis? 88
Predictors of Response to Hydroxyurea and Switch to Ruxolitinib in HU-Resistant Polycythaemia VERA Patients: A Real-World PV-NET Study 87
G20210A protrombin gene variant and clinical outcome in patients with a first acute coronary syndrome 87
Venous thromboembolism in patients with liver diseases 86
Real-world use of thrombopoietin receptor agonists in elderly patients with primary immune thrombocytopenia 86
Risk factor and etiology analysis of ischemic stroke in young adult patients 84
G20210A prothrombin gene variant and clinical outcome in patients with a first acute coronary syndrome 84
Splanchnic vein thromboses associated with myeloproliferative neoplasms: An international, retrospective study on 518 cases 78
Platelet cut-off for anticoagulant therapy in thrombocytopenic patients with blood cancer and venous thromboembolism: An expert consensus 76
Influence of proband's characteristics on the risk for venous thromboembolism in relatives with factor V Leiden or prothrombin G20210A polymorphisms 74
Second cancers in MPN: Survival analysis from an international study 73
JAK2V617F variant allele frequency >50% identifies patients with polycythemia vera at high risk for venous thrombosis 66
Neutrophil-to-lymphocyte ratio is a novel predictor of venous thrombosis in polycythemia vera 63
Left atrial myxoma supplied from the right coronary artery 58
ROLE OF 18 F-FDG PET/CT IN THE ASSESSMENT OF PATIENTS WITH SMOLDERING MULTIPLE MYELOMA 57
Glycoprotein IA C807T gene polymorphism and increased risk of recurrent acute coronary syndromes: a five year follow up. 56
High Frequency of Germline ATM Variants in Familial Philadelphia-Negative Myeloproliferative Neoplasms 53
Correspondence between neurophysiological and clinical measurements of chemotherapy-induced peripheral neuropathy: secondary analysis of data from the CI-PeriNomS study 18
Impact of ELN clinical signs and symptoms on the thrombotic risk in polycythemia vera patients treated with front-line hydroxyurea 4
The impact of daratumumab-containing induction on stem cell mobilization, collection and engraftment in newly diagnosed multiple myeloma: results of the prospective DILEMMA study 2
null 1
Totale 10.764
Salva come PNG Salva come JPEG
Categoria #
all - tutte 45.150
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 45.150
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202114 0 0 0 0 0 0 0 0 0 0 0 14
2021/2022668 46 35 16 40 32 13 20 80 45 45 121 175
2022/20231.356 203 197 115 199 77 159 79 84 154 25 35 29
2023/2024742 28 177 30 52 34 127 37 40 14 31 80 92
2024/20251.552 26 67 91 62 121 37 59 71 254 165 325 274
2025/20264.480 601 120 319 416 916 191 705 216 281 293 212 210
Totale 10.764